News

CGeneTech Receives Project Support from the "13th Five-Year Plan National Major New Drug Creation Project

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-12-07
  • Views:0

(Summary description)Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

CGeneTech Receives Project Support from the "13th Five-Year Plan National Major New Drug Creation Project

(Summary description)Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-12-07
  • Views:0

Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

During the "13th Five-Year Plan" period, the "Major New Drug Creation" Science and Technology Major Project mainly focuses on malignant tumors, cardiovascular and cerebrovascular diseases, drug-resistant pathogenic infections, viral infections and other major diseases, with a focus on supporting original drugs with independent intellectual property rights, high clinical value, good market prospects, and in the preclinical and clinical research stages. Based on the long-term development needs, actively translate and apply the latest achievements of basic research related to new drug development at home and abroad, and carry out innovative drug discovery research based on new targets and new mechanisms of action. Drug discovery research.


China is a major diabetic country with more than 100 million diabetic patients, ranking first in the world. CGeneTech (Suzhou, China) Co., Ltd. was approved by the State Food and Drug Administration of China in May 2017 for the clinical trial of Shengliptin phosphate, a Class 1 innovative drug for the treatment of type 2 diabetes. At present, CGeneTech has reached an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the phase I clinical trial of Shenggliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycemia and weight gain, and has cardiovascular protection; at the same time, Chinese patients with type 2 diabetes are more severely damaged by pancreatic β-cells than those in Europe and the United States, and one of the characteristics of DPP-4 inhibitors is that they can improve β-cell damage, thus Chinese patients can benefit more. This has led to the increasing acceptance of DPP-4 inhibitors by physicians in China.


With a team of elites in the biopharmaceutical industry, CGeneTech has developed a new class 1 glucose-lowering drug, Centagliptin, to bring new hope to the 114 million diabetes patients in China. When compared with the best glucose-lowering drugs in the world, Shengliptin outperforms its competitors in terms of efficacy, safety and cost of administration, and is expected to be the first independently developed new diabetes drug approved for marketing in China.

The

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.
2023-04-20

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO